Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2020


	March 31, 2020	March 31, 2019
	(unaudited)	(unaudited)
Common Stock Warrants	2,862,314	2,722,967
Employee Stock Options	237,695	185,081
Preferred Stock	852,500	852,500
Total Shares of Common Stock Issuable	3,952,509	3,760,548

The below table represents the changes in the Company’s contract liabilities:


	Three Months
	Ended
	March 31,
	2019
Revenue recognized in the period from:
Amounts included in contract liability at the beginning of the period	$	2,686,000